An Open-Label Prospective Multi-Center Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi ) With Tremelimumab Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hepatocellular Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
      In order to participate in this trial the following criteria must be met:
    1. 1) Willingness and ability to participate in study intervention.
    2. 2) Diagnosis of localized breast cancer (stage 0-III).
    3. 3) Candidate for curative partial or whole breast or chest wall irradiation lumpectomy or mastectomy.

You may not be eligible for this study if the following are true:

    1. You will not be able to participate in this trial if:
    2. 1) You are participating in an interventional clinical trial which involves topical application of an experimental agent to the radiation field.
    3. 2) You are a vulnerable subject.
    4. 3) Individuals who lack the capacity to consent.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.